• PCT/EP2016/074828. New combination therapies for treating neurological damage. Casas C, Romeo D, Coma M, Pujol A, Mas JM (2016). Empresa que l'està explotant: NeuroHeal S.L.
    EP171584683 and EP171585037. Compounds for treating Synucleinopathies. Dalfó E (2017).
  • EP173825548. Inhibition of α-synuclein aggregation in Parkinson's disease. Dalfó E (2017).
  • EP171519093. Specialized pro-resolving lipid mediators for use in the treatment of neurodegenerative diseases and/or autoimmune diseases. Lopez-Vales R, Martinez-Muriana A, Sanchez-Fernandez A (2017).
  • EP183824275. Circulating miRNAS as biomarkers for diagnosis of mild cognitive impairment and Alzheimer’s disease. Rodriguez-Alvarez J, Miñano-Molina AJ, Siedlecki-Wüllich D (2018).
  • EP183822568. Rapid detection of antibiotic resistance by bacterial ribosome immunoprecipitation. Quintana A, Sanz E (2018).
  • EP193820537. Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases. Puighermanal E, Quintana A, Sanz E (2019).
  • PCT/IL2019/050913. Vectors expressing klotho for treating cancer. Abraham C, Abraham M, Bosch A, Chillón M, Rubinek T, Wolf I (2019)
  • EP19382435.6. Composition for use in the treatment and/or prevention of muscle and/or tendinous disorders. Casas C, Romeo D, Marmolejo S (2019). Empresa que l'està explotant: NeuroHeal S.L